Transce3nd’s DexCom DXCM Stock Holding History

Transce3nd’s Portfolio DXCM Stock Details DXCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-141	Closed	-$12.3K	–	417
2025 Q2	$12.3K	Buy	141 +68	+93%	+$5.33K	0.01%	531
2025 Q1	$4.99K	Buy	73 +23	+46%	+$1.88K	﹤0.01%	724
2024 Q4	$3.89K	Buy	+50	New	+$3.7K	﹤0.01%	978

Other funds holding DXCM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Transce3nd's DXCM Position: Q3 2025 in Review

Transce3nd sold out of DexCom (DXCM) in Q3 2025, closing a stake of 141 shares — an estimated $12.3K sold.

Transce3nd first reported a position in DXCM in Q4 2024 and held it in 3 quarters. The position peaked at $12.3K in Q2 2025. 911 funds tracked by Wall St. Rank hold DXCM as of Q3 2025.

Transce3nd reported no remaining DexCom position as of Q3 2025 after selling out during the quarter.
Transce3nd sold 141 DexCom shares in Q3 2025, an estimated $12.3K.
Transce3nd first reported a position in DexCom in Q4 2024 and held it in 3 quarters.
Transce3nd's DexCom position peaked at $12.3K in Q2 2025.
911 funds tracked by Wall St. Rank held DexCom as of Q3 2025.

Based on Transce3nd's 13F filing for Q3 2025, filed 12 Nov 2025.